TISLELIZUMAB Combined With Anlotinib and Chemotherapy(XELOX) in the Treatment of Advanced Gastric Carcinoma
This is a Phase 2, multi-cohort study to investigate safety, anti-tumor activity of the monoclonal antibody BGB A317 in combination with Anlotinib and standard chemotherapy as first-line treatment in Gastric, or Gastroesophageal Junction Carcinoma. The study includes a screening (up to 28 days), treatment (until disease progression, intolerable toxicity, or treatment withdrawal for another reason), safety follow-up (up to 30 days following last study drug treatment), and survival follow-up phase.
Gastric Cancer
DRUG: BGB-A317|DRUG: Anlotinib|DRUG: Oxaliplatin|DRUG: Capecitabine
MTD, Maximum tolerated dose, 6 months|ORR, Proportion of patients with reduction in tumor burden of a predefined amount, including complete remission and partial remission, through study completion, an average of 18 month
Overall Survival, Overall survival was measured from the initiation of chemotherapy to the date of the last follow-up or death., up to 2 years|Progression-free survival, he PFS was calculated from the initiation of chemotherapy to the date of disease progression or death., up to 2 years
This is a Phase 2, multi-cohort study to investigate safety, anti-tumor activity of the monoclonal antibody BGB A317 in combination with Anlotinib and standard chemotherapy as first-line treatment in Gastric, or Gastroesophageal Junction Carcinoma. The study includes a screening (up to 28 days), treatment (until disease progression, intolerable toxicity, or treatment withdrawal for another reason), safety follow-up (up to 30 days following last study drug treatment), and survival follow-up phase.